 Neuromyelitis Optica
"Neuromyelitis Optica" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.
| Descriptor ID |
D009471
|
| MeSH Number(s) |
C10.114.375.600.500 C10.114.375.800 C10.292.700.550.500 C10.314.350.600.500 C10.314.350.800 C11.640.576.695 C20.111.258.250.550.500 C20.111.258.250.775
|
| Concept/Terms |
Neuromyelitis Optica- Neuromyelitis Optica
- NMO Spectrum Disorder
- NMO Spectrum Disorders
- Neuromyelitis Optica (NMO) Spectrum Disorder
- Neuromyelitis Optica Spectrum Disorders
- Neuromyelitis Optica (NMO) Spectrum Disorders
- Devic Neuromyelitis Optica
- Devic Neuromyelitis Opticas
- Neuromyelitis Optica, Devic
- Neuromyelitis Opticas, Devic
- Devic Disease
- Disease, Devic
- Devic Syndrome
- Syndrome, Devic
- Devic's Syndrome
- Devics Syndrome
- Syndrome, Devic's
- Devic's Neuromyelitis Optica
- Devics Neuromyelitis Optica
- Neuromyelitis Optica, Devic's
- Neuromyelitis Optica Spectrum Disorder
- Devic's Disease
- Devics Disease
- Disease, Devic's
|
Below are MeSH descriptors whose meaning is more general than "Neuromyelitis Optica".
Below are MeSH descriptors whose meaning is more specific than "Neuromyelitis Optica".
This graph shows the total number of publications written about "Neuromyelitis Optica" by people in this website by year, and whether "Neuromyelitis Optica" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 8 | 1 | 9 | | 2012 | 9 | 0 | 9 | | 2013 | 5 | 1 | 6 | | 2014 | 5 | 0 | 5 | | 2015 | 6 | 0 | 6 | | 2016 | 6 | 0 | 6 | | 2017 | 4 | 3 | 7 | | 2018 | 1 | 0 | 1 | | 2019 | 6 | 0 | 6 | | 2020 | 7 | 0 | 7 | | 2021 | 6 | 0 | 6 | | 2022 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuromyelitis Optica" by people in Profiles.
-
Herwerth M, Kenet S, Schifferer M, Winkler A, Weber M, Snaidero N, Wang M, Lohrberg M, Bennett JL, Stadelmann C, Hemmer B, Misgeld T. A new form of axonal pathology in a spinal model of neuromyelitis optica. Brain. 2022 06 03; 145(5):1726-1742.
-
Mader S, Brimberg L, Vo A, Strohl JJ, Crawford JM, Bonnin A, Carrión J, Campbell D, Huerta TS, La Bella A, Berlin R, Dewey SL, Hellman M, Eidelberg D, Dujmovic I, Drulovic J, Bennett JL, Volpe BT, Huerta PT, Diamond B. In utero exposure to maternal anti-aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. Sci Transl Med. 2022 04 20; 14(641):eabe9726.
-
Liu YH, Guo YC, Lin LY, Tsai CP, Fuh JL, Wang YF, Chen SP, Wu HM, Yu KW, Lin KP, Wang SJ, Liao YC, Lee YC. Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder. J Formos Med Assoc. 2022 Sep; 121(9):1647-1656.
-
Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk DM, Green AJ, Fujihara K, Cutter G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022 Jan; 57:103356.
-
Aktas O, Smith MA, Rees WA, Bennett JL, She D, Katz E, Cree BAC. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol. 2021 05; 89(5):895-910.
-
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2021 05; 8(3).
-
Winkler A, Wrzos C, Haberl M, Weil MT, Gao M, Möbius W, Odoardi F, Thal DR, Chang M, Opdenakker G, Bennett JL, Nessler S, Stadelmann C. Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration. J Clin Invest. 2021 03 01; 131(5).
-
Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021 11; 27(13):2052-2061.
-
Rempe T, Tarhan B, Rodriguez E, Viswanathan VT, Gyang TV, Carlson A, Tuna IS, Rees J. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience. Mult Scler Relat Disord. 2021 Feb; 48:102718.
-
Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T, Yamamura T. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020 09 03; 7(5).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|